Goldman Sachs downgraded Dr. Reddy’s (RDY) to Sell from Neutral with a INR 1,075 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s awaiting approval for Semaglutide in Canada, CNBC-TV18 says
- Dr. Reddy’s rally on CNBC report overstates upside, says Citi
- Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure
- Dr. Reddy’s Divests Svaas Wellness Subsidiary in Small April 2026 Deal
- Dr. Reddy’s Allots Equity Shares Under ESOP on March 26, 2026